To maximize the commercial potential of the Medici Drug Delivery System, Intarcia continues to evaluate new opportunities for novel and proprietary product candidates, with efforts focused around two areas:

  • Evaluation of new applications of the Medici Drug Delivery System to develop products for which we can hold exclusive development and commercialization rights; and
  • Exploration of collaborative opportunities with partners to which our formulation and drug delivery technology and expertise can lend enhancement of life-cycle management, product line extension or a competitive edge.

To learn more about Intarcia's partnering opportunities please contact Intarcia Business Development at

Pipeline News

Intarcia Acquires Phoundry Pharmaceuticals
Acquisition of world class peptide team and library of optimized peptide assets creates opportunity for "NextGen" ITCA 650 combo therapy targeting diabetes and obesity. Other important diseases to be explored for mid and long-term pipeline.

Intarcia and Numab Sign Multi-Asset Collaboration to Develop Once-Yearly Therapies
Collaboration combines Intarcia’s proprietary delivery technologies with Numab’s novel multi-specific antibody technology.